

1 **Identification of consensus head and neck cancer-associated microbiota signatures: a**
2 **meta-analysis of 16S rRNA and The Cancer Microbiome Atlas datasets.**

3 Kenny Yeo ^{1,2}, Runhao Li^{1,3}, Fangmei Wu^{1,3}, George Bouras², Linh T.H. Mai^{1,2}, Eric
4 Smith^{1,3}, Peter-John Wormald^{1,2}, Rowan Valentine², Alkis James Psaltis^{1,2}, Sarah Vreugde^{1,2},
5 and Kevin Fenix^{1,2}

6 (1) Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide,
7 SA, 5000, Australia

8 (2) Department of Surgery- Otolaryngology Head and Neck Surgery, The University of
9 Adelaide and the Basil Hetzel Institute for Translational Health Research, Central Adelaide
10 Local Health Network, Adelaide, SA, 5000, Australia

11 (3) Department of Haematology and Oncology, Basil Hetzel Institute for Translational Health
12 Research and The Queen Elizabeth Hospital, Central Adelaide Local Health Network,
13 Adelaide, SA, 5000, Australia

14

15 **Corresponding author:**

16 Kevin Fenix

17 Email: kevin.fenix@adelaide.edu.au

18 **Word count:** 6021

19

20

21

22

23

24

25

26 **Highlights:**

- 27 • The first meta-analysis of tissue microbiome in head and neck cancer containing eleven
28 16S ribosomal RNA and The Cancer Microbiome Atlas dataset.
- 29 • Microbiome from head and neck tissues were able to distinguish tissue types (cancer,
30 cancer-adjacent, non-cancer) using 16S rRNA sequencing and whole genome sequencing
31 datasets.
- 32 • Specific bacterial genera correlate with different tumour microenvironment phenotypes.
- 33 • High abundance *Fusobacterium* in tumour tissue correlates with better overall survival.

34

35 **Abstract:**

36 **Objective:** Multiple reports have attempted to describe the tumour microbiota in head and
37 neck cancer. However, these have failed to produce a consistent microbiota signature which
38 may undermine understanding the importance of bacterial-mediated effects in head and neck
39 cancer. The aim of this study is to consolidate these datasets and identify a consensus
40 microbiota signature in head and neck cancer.

41 **Methods:** We analysed 11 published head and neck cancer 16S ribosomal RNA microbial
42 datasets collected from cancer, cancer-adjacent and non-cancer tissue to generate a consensus
43 microbiota signature. These signatures were then validated using The Cancer Microbiome
44 Atlas database.

45 **Results:** We identified unique bacteria enrichment within tissue types and correlated it with
46 possible functional and clinical outcomes.

47 **Conclusions:** Our meta-analysis demonstrates a consensus microbiota signature for head and
48 neck cancer, highlighting its potential importance in this disease.

49

50 **Keywords:** Tumour Microbiota, Head and Neck Cancer, 16s rRNA Sequencing, Meta-
51 Analysis

53 1. Introduction

54 Recent studies have revealed that cancers previously thought to be sterile can contain unique
55 microbial communities. The extent of microbial infiltration varies across different cancer
56 types, with head and neck cancers (HNSC) containing one of the highest level of intratumoral
57 microbial infiltrates while glioblastomas having the least amount of microbes.¹⁻³ This
58 “intratumoral microbiota” can refer to bacterial infiltrates found in the extracellular matrix or
59 within the cellular components of the tumour such as cancer, immune and stromal cells.² It is
60 now widely appreciated that intratumoral bacteria can have direct and indirect effects on
61 tumours or the tumour microenvironment (TME).⁴⁻⁶ The presence of specific intratumoral
62 bacteria has been reported to influence multiple features of tumour biology including
63 treatment efficacy, local immune composition and activity and promoting tumour
64 metastasis.⁷⁻¹⁰

65
66 Direct interaction between specific bacterial species with the tumour and the TME can induce
67 chemoresistance, promote tumour progression, enhance therapeutic responses and modulate
68 anti-tumour immunity through various mechanisms.¹¹⁻¹⁴ Bacteria can metabolise an active
69 drug into its inactive form or induce autophagy in cancer cells which can promote
70 chemoresistance.¹²⁻¹⁴ Moreover, specific bacterial species can mount or suppress anti-tumour
71 responses.¹⁵⁻¹⁷ Most notably, *Fusobacterium nucleatum* colocalises with cancer and immune
72 cells by binding to cell surface receptors such as Toll-like receptor 4 (TLR-4), T-cell
73 immunoreceptor with Ig and ITIM domains (TIGIT) and Carcinoembryonic Antigen-Related
74 Cell Adhesion Molecule 1 (CEACAM-1) receptors, or sugar groups (e.g. tumour expressed
75 Galactose-N-acetylgalactosamine), which may then promote chemoresistance and suppress
76 anti-tumour immunity^{13, 15, 18-22}. Alternatively, *Bifidobacterium species* enhance anti-tumour
77 immunity and efficacy of PD-1 immunotherapy responses.^{8, 23, 24}

78

79 The release of bacterial metabolites such as short chain fatty acids (SCFA), amino acids,
80 vitamins and bile acids can indirectly affect the tumour and the TME.^{25, 26} Butyrate, a SCFA
81 released by anaerobic bacteria through fermentation of carbohydrates, can decrease tumour
82 cell growth and invasion, while increasing CD8⁺ T cell-mediated anti-tumour responses.²⁷⁻³⁰
83 However, butyrate has also been shown to have pro-tumorigenic effects by inducing
84 senescence-associated inflammatory phenotypes and inhibiting natural killer cell functions.³¹
85 ³² Bacteria-derived indole and its derivatives (i.e. indole-3-lactic acid) have been shown to
86 suppress anti-tumour immunity by activating immunosuppressive tumour-associated
87 macrophages in treatment-naïve pancreatic cancer, while improving chemotherapeutic and
88 immune-checkpoint inhibitor efficacy in pancreatic cancer and melanoma.³³⁻³⁵ Together,
89 these studies demonstrate that the tumour microbiota can influence cancer clinical outcomes
90 in a context-dependent manner.

91

92 There are multiple reports describing the microbiota in HNSC.³⁶⁻⁸⁹ Most of these studies
93 compared the microbiota diversity and bacterial relative abundance between cancer and
94 healthy samples using 16S ribosomal RNA (rRNA) sequencing^{36-85, 88, 89}, while two studies
95 additionally correlated the impact of the microbiota with matched transcriptome analysis.^{86, 90}
96 Samples studied include tissues, swabs, and oral fluids (saliva or oral rinse) from cancer and
97 healthy patients. Specifically for HNSC tissue microbiota analysis, samples included cancer,
98 cancer-adjacent (approximately > 5 mm away from the tumour), contralateral, and healthy
99 donor tissue samples.^{36-55, 57-60, 85-89} Most bacteria identified in HNSC are oral commensal
100 bacteria from the genera *Streptococcus*, *Rothia*, *Fusobacterium*, *Haemophilus* and
101 *Prevotella*.³⁶⁻³⁸ However, changes in microbial composition have been identified when cancer
102 samples are compared to healthy controls. In general, there was an enrichment in

103 *Fusobacterium* within cancer tissue samples, that correlated with an inflammatory
104 phenotype.^{36, 37, 47} However, inconsistencies are observed for microbes such as *Streptococcus*,
105 *Actinomyces* and *Prevotella* warranting the need to identify a consensus microbiota signature
106 for HNSC.^{37, 38, 43, 54, 85}

107

108 In this study, we systematically reviewed the literature and performed a meta-analysis to
109 consolidate the currently heterogeneous HNSC-associated microbiota data. Selected 16s rRNA
110 sequencing datasets were analysed consistently to minimise variability between different
111 sample cohorts and adjusted for batch-effects.⁹¹ These consensus HNSC-associated microbial
112 signatures were then validated using whole genome sequencing (WGS) data from The Cancer
113 Microbiome Atlas (TCMA).¹ Finally, we correlated the presence of different microbiota
114 signatures with the HNSC tumour microenvironment and clinical outcomes.


115 2. Methods

116 This study was performed according to the Preferred Reporting Items for Systematic Reviews
117 and Meta-Analyses (PRISMA) Statement.⁹²

118 2.1 Search and Study Selection

119 The following criteria were used to select datasets: 1) Tissue samples, 2) Presence of
120 metadata to distinguish sample types, 3) Illumina short-read amplicon sequencing of 16S
121 rRNA V3 to V5 primers (Figure 1). Database search was performed on 16 August 2022 and
122 datasets after this date were not included (Supplementary Table 1). The risk of biasness
123 assessment was conducted using RoB 2 (β v9) (Supplementary Table 1).

124
125



126
127
128

Figure 1: Study selection flow chart.

129

130 2.2 Download, pre-processing, and analysis of 16S rRNA datasets

131 Previously published raw sequences were retrieved from the National Center for
132 Biotechnology Information (NCBI) Sequence Read Archive (SRA) using pysradb.⁹³ Samples
133 were divided into three main groups – cancer, cancer-adjacent and non-cancer tissues. Cancer
134 tissues are defined as tissues obtained directly from the tumour, while cancer-adjacent tissues
135 are cancer-free regions obtained > 5mm away from cancer tissues. Non-cancer tissues are
136 defined as tissues that were either obtained from healthy patients or contralateral tissues
137 obtained from cancer patients. FASTQ sequences files were obtained from SRA using
138 sratoolkit.⁹⁴ These sequences were processed using QIIME2 DADA2 denoise-paired and
139 reads truncated using the same parameters (trim_left_f = 30, trim_left_r = 30, trunc_q = 15).
140 Sequences from different studies were merged before bacterial Operational Taxonomic Units
141 (OTU) classification using QIIME2 and SILVA reference database (version silva-138-99-nb-
142 classifier).⁹⁵

143

144 Raw microbial reads were filtered, central log-ratio (CLR) transformed and batch-adjusted
145 using Phyloseq and MixOmics as described previously.⁹⁶⁻⁹⁸ Microbiome datasets are
146 inherently compositional, hence, CLR transformation addresses generates scale-invariant
147 values which allows datasets to remain unaffected by variations in library sizes among
148 samples.⁹⁹ Briefly, low abundance of OTUs were filtered through proportional counts of all
149 samples (< 1%) and minimum counts per sample (< 10). Bacterial OTUs were agglomerated
150 at the genus level before transforming into CLR for their compositional nature.^{96, 98} The CLR-
151 abundance was used for subsequent statistical and discriminant analysis. A total of 903 SRA
152 samples from 11 projects were downloaded (Table 1).

153

154

155

156

157

158 **Table 1: Study accession and sample size post-filtering**

159

160

Accession number	Sample size			Primers
	Cancer	Cancer-adjacent	Non-cancer	
PRJNA412445	16	0	0	V4 -V5
PRJNA555458	0	0	4	V3 -V4
PRJNA596113	102	53	0	V3 -V4
PRJNA597251	19	20	0	V3 -V4
PRJNA666746	50	50	0	V3 -V4
PRJNA666891	7	0	10	V4
PRJNA685226	13	13	0	V3 -V4
PRJNA699728	37	0	201	V4
PRJNA803155	40	0	0	V4 -V5
PRJNA822685	75	79	0	V3 -V4
PRJNA866676	37	36	41	V3 -V4

166

167 2.3 Discriminant analysis of 16S rRNA dataset

169 To discriminate the microbial signature between sample types, we employed both
170 multivariate and univariate discriminant analysis. For β -diversity analysis, CLR-abundance of
171 all genera were ordinated using Euclidean distance and plotted on a principal component
172 analysis (PCA) using mixOmics R package. β -diversity for each sample were calculated as
173 distance to centroid for each tissue groups using betadisper (vegan v2.6-4). Group and
174 pairwise permutest (vegan v2.6-4, permutations = 9999) was performed to determine if
175 dispersions differed between sample types, while group and pairwise permutational
176 multivariate analysis of variance (PERMANOVA) was performed using adonis2 (vegan v2.6-
177 4, method = "euclidean", permutation = 9999) and pairwise.adonis2 (pairwiseAdonis, method
178 = "euclidean", permutation = 9999) to determine statistical differences in β -diversity between
179 groups. Other statistical test such as Analysis of similarities (ANOSIM) (vegan v2.6-4,
180 distance = "euclidean", permutation = 9999) and Fifty-fifty multivariate analysis of variance
181 (FFMANOVA) (nSim = 9999) were also applied as supplementary to distinguish between
182 sample types.^{100, 101}

183 Multivariate sparse partial linear discriminant analysis (sPLS-DA) was applied on batch-
184 adjusted dataset to identify discriminating genera within each sample type.⁹⁶ The Area Under
185 Curve (AUC) of the Receiver Operating Characteristics (ROC) curve was calculated using
186 mixOmics in Rstudio.^{96, 98} The AUC value served as a quantification of the discriminatory
187 potential between sample types. A higher AUC value, closer to 1, signified a test approaching
188 perfection in its ability to distinguish between the samples. Heatmap of all representative
189 bacteria in each sPLS-DA was presented with sample type clustered according to Euclidean
190 distance and Ward's linkage.

191

192 Univariate Kruskal-Wallis test with Bonferroni multiple comparisons test was also performed
193 to determine microbial genera differences between sample types using microbiomeMarker in
194 Rstudio v3.3.0, followed by a post-hoc Wilcoxon test (Mann-Whitney test) with Bonferroni-
195 Dunn multiple comparison test to determine differences between groups (cancer– cancer-
196 adjacent, cancer – non-cancer, non-cancer – cancer-adjacent). Additionally, Wilcoxon
197 matched-pairs signed rank test with Bonferroni-Dunn multiple comparison test was also
198 performed on paired cancer and cancer-adjacent samples.

199

200 **2.4 Functional profiling analysis of 16S rRNA datasets in different sample types**

201 To predict the microbial functions of genera detected from 16S rRNA sequencing between
202 each tissue sample type, Phylogenetic Investigation of Communities by Reconstruction of
203 Unobserved States 2 (PICRUST2) from QIIME2 was applied on raw 16S rRNA reads using
204 MetaCyc database.^{102, 103} Functional abundance was processed and analysed similarly as
205 described for raw microbial reads. Univariate Kruskal-Wallis test and post-hoc Wilcoxon test
206 was performed as previously described to compare differences between groups.

207

208 **2.5 Reanalysis of tissue microbiome data from TCMA**

209 Decontaminated microbial read count derived from The Cancer Genome Atlas (TCGA)
210 HNSC whole genome sequences were obtained from TCMA repository.¹ Data from a total of
211 177 cancer (TCGA annotation: primary tumour) and 22 cancer-adjacent (TCGA annotation:
212 solid tumour normal) tissues were obtained from TCMA repository (n = 22 paired cancer and
213 cancer-adjacent samples). Similar to 16S rRNA pre-processing, read counts were
214 agglomerated to the genus before CLR transformation as described in 2.2. As samples were
215 already pre-processed in the TCMA dataset, no further filtering or batch adjustment was
216 required. Microbiome statistical analysis were performed similarly as 16S sequencing
217 datasets. Metadata were obtained from cBioPortal for Cancer Genomics.¹⁰⁴

218

219 **2.6 Microbiome correlation analysis with tumour microenvironment and survival** 220 **analysis**

221 The TME immune subtype and 29 functional gene expression signatures (FGES) scores were
222 previously described by Bagaev et al. (2021) using transcriptomics datasets from TCGA.¹⁰⁵
223 The 29 FGES represents the major functional components and immune, stromal, and other
224 cellular populations of the tumour.¹⁰⁵ Pearson's correlation test was applied to determine the
225 correlation between FGES scores and selected bacteria genera. The four TME immune
226 subtypes were – Desert (D), Fibrotic (F), Immune-enriched (IE), Immune-enriched/Fibrotic
227 (IE/F) (Described in Supplementary Table 2).¹⁰⁵ Specifically, tissues with IE and IE/F
228 phenotype contains high T-cell infiltration, while D and F phenotypes have low T-cell
229 infiltration (Supplementary Table 2).¹⁰⁵ Using a cut-off of high (top 35th percentile) and low
230 (bottom 35th percentile) CLR-abundance, the proportion of each patient within the four TME
231 subtypes were determined, and survival analysis was performed. Since there were 153
232 TCGA-HNSC samples with both FGES/TME subtypes and microbiome datasets, these

233 samples were used for subsequent correlation and survival analysis. Chi-squared (χ^2) test was
234 performed in Prism9 to determine association between high/low bacterial genera CLR-
235 abundance and proportion of patients within each tumour subtype.

236

237

238

239 **2.7 Statistical analysis**

240 For comparisons made between all unpaired tissue groups, Kruskal-Wallis test with
241 Bonferroni's multiple comparison was used for comparisons made between all tissue groups
242 unless stated otherwise. Post hoc Wilcoxon matched pairs signed rank test with Bonferroni's
243 multiple comparison was used to compare differences between unpaired tissue samples. For
244 all paired cancer and cancer-adjacent samples, Wilcoxon matched-pairs signed rank test was
245 performed. Univariate and multivariate Cox proportional hazard model was performed using
246 survminer in Rstudio v3.3.0. Statistical analysis was performed using RStudio v3.3.0 and
247 Prism9.

248

249 **3 Results**


250 **3.1 Multivariate analysis identifies homogenous microbial abundance and functions between** 251 **cancer and cancer-adjacent samples, contrasting to non-cancer samples.**

252 The 16S rRNA amplicon datasets were obtained for 903 head and neck tissue types (396
253 cancer, 251 cancer-adjacent, and 256 non-cancer) from 11 studies.^{37, 38, 41-45, 87-89} Following
254 sample processing and aggregation of 16S data at the genus level, a total of 177 distinct
255 bacterial genera were identified. Differences in the microbiota and β -diversity between tissue
256 types were assessed using PCA and PERMANOVA test (Figure 2A-2B). The β -diversity
257 index was calculated for cancer (14.6 ± 5.7) and cancer-adjacent (15.0 ± 5.5) tissues,
258 revealing similar levels of β -diversity. In contrast, non-cancer tissues (8.61 ± 5.3) exhibited
259 lower β -diversity (PERMANOVA – Overall $R^2 = 0.006$, $p < 0.0001$) (Figure 2B). Post-hoc
260 pairwise test identified significant differences in β -diversity between cancer and non-cancer
261 ($R^2 = 0.003$, $p = 0.002$), cancer and cancer-adjacent ($R^2 = 0.005$, $p < 0.001$), and non-cancer
262 and cancer-adjacent samples ($R^2 = 0.007$, $p < 0.001$) (Figure 2B). These findings were
263 consistent with additional multivariate and univariate statistical analysis, ANOSIM ($R =$
264 0.027 , $p = 0.002$) and FFMANOVA ($p < 0.0001$) (Supplementary Table 3).

265

266 Multivariate sparse partial least squares discriminant analysis (sPLS-DA) identified 116
267 representative bacterial genera in sPLS-DA component 1 and 2 which were discriminant
268 between tissue types (Figure 2C-E). The AUC values were computed for different sample
269 comparisons: cancer versus others (AUC = 0.74, $p < 0.05$), non-cancer versus others (AUC =
270 0.91, $p < 0.05$), and cancer-adjacent versus others (AUC = 0.84, $p < 0.05$). These results
271 demonstrate that sPLS-DA components 1 and 2 (Figure 2D) can effectively differentiate
272 between tissue types. Lastly, majority of cancer and cancer-adjacent samples clustered

273 together and were distinct from non-cancer samples, as determined by Euclidean distance
 274 metric (Figure 2E).



275

276 **Figure 2: Multivariate discriminant analysis (sPLS-DA and PERMANOVA) of tissue**
277 **16S rRNA microbiota to discriminant between cancer, cancer-adjacent and non-cancer**
278 **tissues.** (A) Principal coordinates analysis (PCA) plot of tissue CLR-abundance microbiota
279 based on Euclidean distance. (B) Dispersion of β -diversity (top-right panel) for each sample
280 type, with error bar representing 95% confidence interval. PERMANOVA test was
281 performed with bacterial genera as variable for sample types. (C) sPLS-DA sample plot of
282 16S rRNA tissue microbiota. Ellipse displays 95% confidence interval for each sample group.
283 The batch-adjusted normalized abundance of tissue microbiota from 16S amplicon
284 sequencing was compared between cancer, cancer-adjacent and non-cancer tissue samples.
285 sPLS-DA identified 116 bacterial genera on component 1 and 2. (D) ROC curve and AUC
286 values determined from sPLS-DA analysis was used to access discriminatory potential of
287 sPLS-DA component 1 and 2. (E) Heatmap representing 86 bacterial genera after sPLS-DA
288 discriminant analysis. Each column and row represent a unique sample and bacterial genera
289 respectively, with OTUs clustered based on Euclidean distance and Ward linkage method.

290

291 **3.2 Univariate analysis identifies differences in microbial abundance and functions**
292 **between sample types.**

293 Next, unpaired univariate analysis was applied to determine the differences between tissue
294 types. Out of the 177 bacterial genera, 33 were identified as significantly different among
295 tissue types using Kruskal-Wallis test ($P_{\text{adjust}} < 0.05$) (Supplementary Table 4). Notably, 18 of
296 these were also identified as representative bacterial genera in sPLS-DA discriminant
297 analysis (Supplementary Table 4). These 33 genera are denoted as bacterial genera of interest
298 (Supplementary Table 4). The top 20 differentially abundant genera, based on the effect size
299 (η^2), are presented in Figure 3. Post-hoc unpaired Wilcoxon test with Bonferroni-Dunn's
300 multiple comparison test was performed on these genera to determine the mean differences in
301 the central log ratio transform (CLR) abundance between tissue types (Figure 3A,

302 Supplementary Table 5). Since most published studies compared cancer to non-cancer, or
303 cancer to cancer-adjacent tissues, we performed post-hoc test for these comparisons (Figure
304 3B). We identified 27 out of 33 genera as significantly different ($P_{\text{adjust}} (\#) < 0.05$) between
305 cancer and non-cancer tissues (Figure 3A-3B, Supplementary Table 5). Non-cancer tissues
306 contained more *Fretibacterium* (CLR-abundance diff. = 1.42, SE = 0.12), *Stenotrophomonas*
307 (CLR-abundance diff. = 0.80, SE = 0.12) and *Tannerella* (CLR-abundance diff. = 0.71, SE =
308 0.10), while cancer tissue had a greater CLR-abundance of *Neisseria* (CLR-abundance diff. =
309 2.32, SE = 0.15), *Capnocytophaga* (CLR-abundance diff. = 2.02, SE = 0.15), and
310 *Streptococcus* (CLR-abundance diff. = 1.98, SE = 0.19) (Figure 3A-3B). *Capnocytophaga*
311 abundance in cancer tissues was consistent to previous findings^{46, 57, 85}, while contradicting
312 findings were identified for the abundance for *Streptococcus*^{38, 41, 52, 57, 85} and
313 *Fusobacterium*^{38, 41, 42, 52, 57, 58}.

314

315 For cancer and cancer-adjacent tissue, 13 out of 33 bacterial genera were significantly
316 different (post-hoc unpaired Wilcoxon test $P_{\text{adjust}} (*) < 0.05$) (Figure 3A and 3C,
317 Supplementary Table 5). Similar to many studies, *Fusobacterium* (CLR-abundance diff. =
318 1.11, SE = 0.20) displayed significantly higher CLR-abundance in cancer tissue than cancer-
319 adjacent tissue, while *Rothia* (CLR-abundance diff. = 0.92, SE = 0.18), *Stenotrophomonas*
320 (CLR-abundance diff. = 1.33, SE = 0.15) and *Serratia* (CLR-abundance diff. = 0.70, SE =
321 0.12) had higher CLR-abundances in cancer-adjacent tissue than cancer tissue (Figure 3A).^{36,}
322 ^{37, 43, 45, 52, 55, 58, 59} Additionally, we found that *Prevotella* was elevated in cancer tissue as
323 compared to cancer-adjacent tissues.^{43, 45, 52, 55, 58} Unlike previous studies, we did not observe
324 any significant differences in *Streptococcus* abundance between cancer and cancer-adjacent
325 tissues.^{36, 37, 45, 51, 52, 55, 59}

326

327 Lastly, 28 of the 33 top bacterial genera were significantly different (post-hoc unpaired
328 Wilcoxon test $P_{\text{adjust}} < 0.05$) when comparing non-cancer to cancer-adjacent tissue samples
329 (Figure 3A, Supplementary Table 5). Genera *Neisseria* (CLR-abundance diff. = 2.83, SE =
330 0.19), *Rothia* (CLR-abundance diff. = 1.95, SE = 0.16) and *Streptococcus* (CLR-abundance
331 diff. = 1.95, SE = 0.16) were higher in CLR-abundance in cancer-adjacent, while
332 *Fusobacterium* (CLR-abundance diff. = 1.80, SE = 0.18) and *Prevotella* (CLR-abundance
333 diff. = 1.28, SE = 0.20) were greater in CLR-abundance in non-cancer tissue (Figure 3A).


334

335 To provide functional insights to microbial abundance between cancer tissues and other tissue
336 types, we applied Picrust2 to predict possible differences in MetaCyc pathway functional
337 CLR-abundance.¹⁰² After filtering low abundant functional pathways, we identified a total of
338 365 MetaCyc pathways. Using Kruskal-Wallis test, 162 MetaCyc pathways were identified
339 as significantly different among sample types ($P_{\text{adjust}} < 0.05$) (Supplementary Table 5). Post-
340 hoc analysis identified 129/162 and 7/162 pathways that were significantly different between
341 cancer – non-cancer, and cancer – cancer-adjacent tissues comparisons respectively
342 (Supplementary Table 6).

343

344 Cancer tissues, when compared to non-cancer tissues, were enriched in pathways involving
345 the synthesis of ubiquinol, L-methionine, inosine-5'-phosphate and cysteine and metabolic
346 pathways such as TCA cycle and pentose phosphate pathway, while non-cancer tissues were
347 enriched in the degradation of L-lysine, L-glutamine, N-Acetylglucosamine (GlcNac), N-
348 acetylmannosamine (ManNac), and N-acetylneuraminic acid (Figure 3C). Cancer tissues were
349 more similar to cancer-adjacent tissues, albeit enrichment was identified in pathways
350 involving biosynthesis of ppGpp (guanosine pentaphosphate and tetraphosphate), cis-
351 vaccenate, L-asparatate, L-asparagine, cob(II)yrinate a,c-diamide and CMP-legionaminic acid,

352 and enrichment in pathways involving degradation of pyruvate and L-lysine, when compared
 353 to cancer-adjacent tissues (Figure 3C).



354

355 **Figure 3. Comparison of bacterial CLR-abundance and functional prediction between**
356 **sample types.** (A) Top 20 bacterial genera (based on effect size) in CLR-normalized
357 abundances between sample groups using Kruskal-Wallis test with Bonferroni's multiple
358 comparison. 33 out of 177 genera were identified as significantly different ($P_{\text{adjust}} < 0.05$)
359 using Kruskal-Wallis test. Post-hoc Wilcoxon test with Bonferroni-Dunn's multiple
360 comparison was performed to identify group-wise differences between Cancer – Non-cancer
361 (#), Cancer – Cancer-adjacent (*), Non-cancer – Cancer-adjacent (^). Post-hoc unpaired
362 Wilcoxon test with Bonferroni-Dunn's multiple comparison for (B) bacterial genera and (C)
363 functional CLR-abundance for Cancer – Non-cancer (Top panel), and Cancer – Cancer-
364 adjacent (Bottom panel).


365

366 **3.3 Paired cancer and cancer-adjacent tissues display similar bacterial abundance** 367 **differences using multiple sequencing techniques.**

368 To understand microbial abundance differences between cancer tissue and cancer-adjacent
369 tissue within the same patients, we performed Wilcoxon matched-pairs signed rank test to
370 identify changes in microbial diversity and abundance within paired tissue samples in the 16S
371 rRNA datasets. Similar to unpaired data analysis, no significant differences in microbial β -
372 diversity was identified between the patient's paired cancer and cancer-adjacent tissues
373 (Supplementary Figure 2).

374 However, 76 bacterial genera were significantly different between paired tissue samples
375 (Figure 4A, Supplementary Table 7). Bacterial genera with the greatest differences in CLR-
376 abundance were then identified by using a cut-off of > 0.4 and < -0.4 (Figure 3A). Using this
377 cut-off, we found that *Fusobacterium*, *Prevotella*, *Alloprevotella*, *Catonella*, *Selenomonas*
378 and *Treponema* were elevated in cancer tissue vs cancer-adjacent tissue, while
379 *Stenotrophomonas*, *Rothia*, *Granulicatella*, *Serratia*, *Anoxybacillus*, *Actinomyces* and

380 *Bacteroides* were greater in cancer-adjacent tissue compared to cancer tissue (Figure 4A-4B).
381 Similarly, nine of these bacteria were also found to be significantly different in unpaired
382 tissue analysis (Supplementary Table 4 and 7). Contrary to published studies on unpaired
383 samples, *Streptococcus*, an abundant oral commensal, was not significantly different in our
384 paired sample analysis.^{36, 37, 45, 51, 52, 55, 59}
385 To validate this finding, we probed the publicly available TCMA dataset, a repository
386 containing microbiota reads derived from WGS of tissue samples.¹ Similar to the 16S rRNA
387 dataset, we observed that cancer tissues from TCMA displayed significantly ($p < 0.05$) higher
388 CLR-abundance for genera *Fusobacterium*, *Selenomonas* and *Treponema*, while *Rothia* and
389 *Actinomyces* were elevated ($p < 0.05$) in cancer-adjacent tissues (Figure 4D). In the TCMA
390 dataset, *Anoxybacillus*, *Serratia*, and *Stenotrophomonas* were not present due to pre-analysis
391 filtering, while no significant differences in CLR-abundance were observed for *Prevotella*,
392 *Catonella*, *Alloprevotella*, and *Bacteroides* (Figure 4C). Notably, similar trend in CLR-
393 abundance between cancer and cancer-adjacent samples was still observed for *Prevotella*,
394 *Catonella*, and *Alloprevotella* in TCMA dataset. Overall, 16S rRNA and TCMA WGS
395 dataset showed similar trend for most bacteria genera, regardless of sequencing techniques.



396

397 **Figure 4: Comparison of tissue microbiota in paired cancer and cancer-adjacent tissue**
 398 **samples using different sequencing datasets. (A) Paired Wilcoxon matched-pairs signed**
 399 **rank test on paired 16S rRNA sequencing cancer and cancer-adjacent tissue samples. 76**
 400 **bacteria were significantly different in sample groups ($p < 0.05$) using paired Wilcoxon**
 401 **matched-pairs signed rank test and 13 bacteria genera were identified as top bacteria with**

402 differential CLR-abundance (Diff. CLR-abundance > 0.4 or < -0.4). Blue and red dot points
403 represent bacteria that were higher in abundance in cancer and cancer-adjacent tissues
404 respectively. CLR-abundance of paired cancer and cancer-adjacent samples from (B) 16s
405 rRNA sequencing and (C) TCMA WGS sequencing datasets. Wilcoxon matched pairs signed
406 rank test was performed for both 16s rRNA (n = 287) and TCMA (n = 22) datasets. *p <
407 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

408

409 **3.4 Tissue microbiota diversity correlates with cancer functional gene expression** 410 **signatures.**

411 Since *Fusobacterium*, *Selenomonas*, *Treponema*, *Actinomyces*, and *Rothia* displayed
412 significant differences between paired cancer and cancer-adjacent tissues, we performed
413 correlation analyses to investigate the possible relationship between these genera and the
414 tumour transcriptional profile and patient clinical features found in matched TCGA patients
415 (n = 156).¹⁰⁵ Here, TCGA transcriptomic data were classified into 29 functional gene
416 expression signatures (FGES), which represent major functional components and
417 characteristics of cancer cell populations.¹⁰⁵ These 29 FGES can then be used to further
418 classify cancers into four major immune subtypes (Desert, Fibrotic, Immune-enriched/non-
419 fibrotic, and Immune-enriched/fibrotic).¹⁰⁵ We correlated the CLR-abundance of
420 *Fusobacterium*, *Selenomonas*, *Treponema*, *Actinomyces*, and *Rothia* from TCGA-HNSC
421 patients with their respective FGES scores and immune subtype.

422


423 We first correlated CLR-abundance with the FGE signatures. The CLR-abundance of
424 *Fusobacterium* correlated (r > 0.3, p < 0.0001) with FGES related to angiogenesis,
425 neutrophils and granulocyte traffic (Figure 5A). Other FGES such as matrix remodelling,
426 protumour cytokines, MDSC traffic, M1 signature, antitumour cytokine, MHC1 and EMT

427 signatures also positively correlated ($p < 0.05$) to CLR-abundance of *Fusobacterium* (Figure
428 5A). The CLR-abundance of *Selenomonas* showed a positive correlation ($p < 0.05$) to
429 angiogenesis, neutrophil signature, granulocyte traffic and antitumour cytokines signatures,
430 while negatively correlating ($p < 0.05$) to B cells (Figure 4A). Lastly, CLR-abundance of
431 *Treponema* displayed a negative correlation ($p < 0.05$) to endothelium, T reg traffic, T reg,
432 MHCII, Coactivation molecules, B cells, NK cells, Effector cells and T cells, while positively
433 correlating to ($p < 0.05$) neutrophils and granulocyte traffic (Figure 5A).

434

435 Next, we investigated how CLR-abundance correlated to tissue immune subtyping. Cancer
436 tissues classified as immune deserts (D) and fibrotic (F) which lack immune cell enrichment
437 correlated with higher *Fusobacterium* and *Treponema* CLR-abundance. On the other hand,
438 cancer tissues that are immune-enriched / non-fibrotic (IE) or immune-enriched / fibrotic
439 (IE/F) correlated with greater *Rothia*. No significant correlation in immune subtypes were
440 observed for *Selenomonas* and *Actinomyces* (Figure 5B). To identify the differences in
441 immune subtypes between high and low CLR-abundance of each bacterial genera, we further
442 segregated patients based on the upper and lower 35% CLR-abundance quartiles. As
443 expected, patients with IE and IE/F tumour subtypes showed significant association with low
444 CLR-abundance of *Fusobacterium* (chi-square test, $p = 0.04$). While not reaching statistical
445 significance, more patients with IE and IE/F tumour subtypes have low CLR-abundance of
446 *Selenomonas* (chi-square test, $p = 0.33$) and *Treponema* (chi-square test, $p = 0.11$), opposite
447 to high CLR-abundance for *Rothia* (Figure 5C). Conversely, patients with D and F subtypes
448 had higher CLR-abundance of *Fusobacterium*, *Selenomonas* or *Treponema* (Figure 5C).
449 Lastly, the proportion of patients in each immune subtype were similar in high and low CLR-
450 abundance *Actinomyces* groups. Taken together, these show that *Fusobacterium*,

451 *Selenomonas* or *Treponema* are associated with poor T-cell infiltration compared to *Rothia*
 452 which may have implications in selecting patients suitable for immunotherapy.



453

454 **Figure 5: Correlation analysis of *Fusobacterium*, *Selenomonas*, *Treponema*, *Rothia***
 455 **and *Actinomyces* to the tumour transcriptional profiles.**

456 (A) 29 functional gene expression (FGES) signature scores derived from Bagaev et al
 457 (2021) were used to correlated with CLR-abundance of genera *Fusobacterium*,
 458 *Selenomonas*, *Treponema*, *Actinomyces*, and *Rothia*, using Pearson's correlation
 459 method. Asterisk (*) represents significant correlation ($p < 0.05$), and red and blue

460 scales represents positive and negative correlation respectively. **(B)** The CLR-
461 abundance of each bacterial genera within each tumour microenvironment immune
462 subtype (D – Desert, F – Fibrotic, IE – Immune-enriched/Non-fibrotic, IE/F – Immune-
463 enriched/Fibrotic). Kruskal-Wallis test with uncorrected Dunn’s test was performed to
464 compare CLR-abundance in all immune groups. * $p < 0.05$, ** $p < 0.01$. **(C)** The
465 proportion of patients in each tumour immune subtype with high and low CLR-
466 abundance in each bacterial genera. High and low bacteria CLR-abundance groups
467 were determined by upper and lower 35% quartiles respectively. Chi-squared test was
468 performed to determine association between high/low bacterial genera CLR-abundance
469 and proportion of patients in each tumour subtype.

470

471 **3.5 Evaluation of microbiota abundance with clinical features and survival**

472 Univariate and multivariate Cox proportional hazard models were used to investigate the
473 association between the intratumoral microbiota and clinical features. Univariate Cox
474 proportional hazard model identified that current smokers (HR 2.235, 95% CI 1.146 – 4.359,
475 $p = 0.018$), HPV-negative (HR 2.273, 95% CI 1.158 – 4.459, $p = 0.017$), and low CLR-
476 abundance of *Fusobacterium* (HR 0.8883, 95% CI 0.8183 – 0.9642, $p = 0.005$) were risk
477 factors for reduced overall survival (Table 2). Further multivariate Cox proportional hazard
478 models identified that HPV-negative (HR 2.853, 95% CI 1.1991 – 6.7882, $p = 0.0178$) and
479 low CLR-abundance of *Fusobacterium* (Continuous: HR 0.8482, 95% CI 0.7758– 0.9273, p
480 $= 0.0003$; Low: HR 2.579, 95% CI 1.3687 – 4.860, $p = 0.0034$) were independent hazards for
481 overall survival, but not current smokers (Table 2).

482

483

484

485 Table 2: Univariate and multivariable Cox proportional hazard models for overall survival


		n	Univariate		Multivariable	
			HR (95% CI)	p-value	HR (95% CI)	p-value
Age (years)	< 65	106				
	≥ 65	47	0.9832 (0.594 – 1.626)	0.947		
Sex	Female	41				
	Male	112	0.868 (0.525 – 1.436)	0.581		
Staging	I	4				
	II	30	2.331 (0.302 – 17.97)	0.417		
	III	31	2.275 (0.2950 – 17.54)	0.430		
	IV	87	3.275 (0.4492 – 23.87)	0.242		
HPV status	Positive	37				
	Negative	107	2.273 (1.158 – 4.459)	0.017*	2.853 (1.1991 – 6.7882)	0.0178*
Smoking	Non-smoker	37				
	Current	43	2.235 (1.146 – 4.359)	0.018*	1.3788 (0.5383 – 3.5317)	0.50329
	Previous	71	1.488 (0.7804 – 2.838)	0.227	0.7821 (0.3130 – 1.9545)	0.59894
	Continuous	153	0.8883 (0.8183 - 0.9642)	0.005**	0.8482 (0.7758– 0.9273)	0.0003**
<i>Fusobacterium</i>	High	53				
	Low	53	2.0592 (1.17 – 3.625)	0.0123*	2.579 (1.3687 – 4.860)	0.0034*
	Continuous		0.9712 (0.8714 – 1.082)	0.597		
<i>Selenomonas</i>	High	53				
	Low	52	1.205 (0.7094 – 2.048)	0.49		
	Continuous	153	0.9467 (0.8768 – 0.719)	0.162		
<i>Treponema</i>	High	53				
	Low	53	1.432 (0.8092 – 2.535)	0.217		
	Continuous	153	1.029 (0.8936 – 1.184)	0.694		
<i>Rothia</i>	High	54				
	Low	54	0.6552 (0.3585 – 1.198)	0.17		
	Continuous	153	0.9652 (0.8512 – 1.094)	0.58		
<i>Actinomyces</i>	High	53				
	Low	52	1.006 (0.5679 – 1.783)	0.983		

486


487 **4 Discussion:**

488 Several studies have investigated the microbial signature in HNSC using different sequencing
489 approaches and sample types, such as tissues, swabs, and oral fluids. However, these studies
490 have reported inconsistent findings regarding the presence of specific bacterial genera.
491 Consequently, a consensus microbial signature for head and neck tissues has yet to be
492 established. In this study, we aimed to address this gap by conducting a meta-analysis of 11
493 studies and presenting a consensus tissue microbiota signature for head and neck tissues. We
494 analyzed 16S rRNA sequencing datasets from 903 tissue samples, including 396 cancer
495 tissues, 251 cancer-adjacent tissues, and 256 non-cancer tissues. Our analysis revealed
496 significant differences in the abundance of 33 bacterial genera among the various tissue
497 types. Specifically, we observed that cancer tissues and cancer-adjacent tissues exhibited
498 greater similarity to each other compared to non-cancer tissues. These findings suggest
499 distinct microbial profiles in cancer and cancer-adjacent tissues compared to non-cancer
500 tissues. Non-cancer tissues exhibited the lowest differences in β -diversity and contained
501 elevated levels of bacterial genera such as *Tannerella*, *Fretibacterium*, *Stenotrophomonas*,
502 *Fusobacterium*, and *Prevotella* (Figure 6A). While cancer and cancer-adjacent tissues
503 displayed similar microbiota based on β -diversity indexes, further analysis using paired and
504 unpaired univariate methods enabled differentiation of these tissues at the genera level
505 (Figure 6B). Importantly, these abundance signatures were validated using additional data
506 from TCMA. Matching TCMA samples with transcriptomic data derived from TCGA) and
507 clinical features provided insights into the contributions of individual genera in HNSC.
508 Notably, we found that a high abundance of *Fusobacterium* was associated with better overall
509 survival in HNSC patients Overall, our study contributes to the establishment of a consensus
510 tissue microbiota signature for HNSC, shedding light on the distinct microbial profiles in
511 different tissue types and their potential implications for clinical outcomes.

(A)



(B)



512

513 **Figure 6: Summary of bacteria genera within cancer, cancer-adjacent and non-cancer**
514 **tissue samples. (A)** Elevated microbiota within non-cancer tissues compared to cancer and
515 cancer-adjacent tissues. **(B)** Elevated bacteria genera between cancer and cancer-adjacent
516 tissues.

517

518 Both multivariate and univariate discriminant analyses was able to differentiate different
519 tissue sample types based on microbial abundance. As previously reported, cancer and
520 cancer-adjacent tissues were more similar in microbial diversity when compared to non-
521 cancer tissues.^{36-38, 42, 43, 45, 49, 51, 52, 55, 57-59, 85} At the genus level, both paired and unpaired

522 abundance analysis of cancer and cancer-adjacent tissues showed consistent enrichment for
523 *Fusobacterium* and *Rothia* in cancer tissues.^{36, 37, 45, 52, 55, 58, 59} In contrast, *Prevotella* was

524 enriched within cancer tissues compared to cancer-adjacent tissues, and no differences were

525 observed for *Streptococcus*.^{36-38, 41, 43, 45, 51, 52, 55, 57-59, 85}

526

527 Previous studies have reported conflicting result where *Fusobacterium* was more in cancer
528 tissues as compared to non-cancer and cancer-adjacent tissues.^{38, 42, 52, 57, 58} However, we
529 found that *Fusobacterium* was most abundant in non-cancer tissues. *Fusobacterium* is an
530 abundant commensal bacteria found largely in the oral cavity (buccal, hard palate, gingiva,
531 tonsils, tongue) and saliva of healthy individuals, suggesting a potential role within the
532 healthy oral microbiota.¹⁰⁶⁻¹⁰⁸ *In vitro* experiments in HNSC cell lines showed that
533 *Fusobacterium nucleatum* infection promotes cancer cell invasion, proliferation, autophagy,
534 and PD-L1 expression.¹⁰⁹⁻¹¹³ It is unknown whether there are strain and species level
535 differences found in *Fusobacterium* isolated in cancer and non-cancer tissues to explain such
536 seemingly contradictory findings. Additionally, non-cancer tissue from cancer patients may
537 also have different tissue microbiota profiles from healthy donor tissues which is currently
538 unavailable for this study. Also, most of the experiments showing an oncogenic role for *F.*
539 *nucleatum* were carried out *in vitro* and thus did not consider a potential mitigating role of the
540 immune system. Moreover, the abundance of *F. nucleatum* both in absolute terms and
541 relative to other bacteria present in the tumour microbiota might influence the oncogenic
542 potential of *F. nucleatum*. Further experiments are required to evaluate the role of
543 *Fusobacterium* in HNSC.

544

545 We observed that *Streptococcus*, another highly abundant oral commensal genera¹⁰⁶⁻¹⁰⁸, was
546 increased specifically in cancer and cancer-adjacent tissue when compared to non-cancer
547 tissues. However, there was no significant difference in *Streptococcus* abundance between
548 cancer and cancer-adjacent tissues. Within the oral cavity, certain pathogenic *Streptococcus*
549 species, like *S. mutans*, can contribute to periodontitis by acidifying the environment.¹¹⁴ In
550 oral cancer, *S. mutans* has been shown to promote tumour proliferation and invasion,

551 potentially through upregulation of IL-6 in infected cells¹¹⁵. On the other hand, *Streptococcus*
552 species from the *mitis* (*S. oralis*, *S. parasanguinis*, *S. mitis*) and *sanguinis* (*S. sanguinis*, *S.*
553 *gordonii*) groups, can break down lactic acid or pyruvate into hydrogen peroxide, thereby
554 antagonising pathogenic species such as *S. mutans*.¹¹⁴ In oral cancer, *S. mitis*, *S. salivarius*, *S.*
555 *anginosus* were found to display anti-tumour effects, including reducing cancer cell viability
556 and promoting CD8⁺ cytotoxic T cell responses¹¹⁶⁻¹²⁰. These findings indicate that the
557 abundance of specific *Streptococcus* species may contribute to pathogenesis, disease severity,
558 or exert anti-tumour effects. It is important to note that these studies underscore the
559 limitations of identifying microbiota at the genus level using short-read 16S rRNA
560 sequencing. To address these limitations, recent advances in sequencing technologies such as
561 long-read 16S rRNA amplicon sequencing (e.g., PacBio, Nanopore) or shotgun
562 metagenomics can be employed to reveal species- or strain-specific diversity within the
563 microbiota.¹²¹⁻¹²³ Such advancements can provide a more comprehensive understanding of
564 the specific species and strains that play a role in oral cancer pathogenesis and anti-tumour
565 effects.

566

567 To compare the metabolic potential of different head and neck tissue types, a functional
568 prediction analysis was performed using PICRUSt2 on the 16S rRNA sequencing data. The
569 analysis revealed an enrichment of several amino acids and metabolites, including L-
570 aspartate, L-asparagine, acetate, butanoate, and lactate, in cancer tissues compared to non-
571 cancer and cancer-adjacent tissues. L-aspartate and L-asparagine, as substrates for nucleotide
572 biosynthesis and regulators of amino acid homeostasis and anabolic metabolism, have been
573 reported to promote tumour proliferation.¹²⁴⁻¹²⁶ Butanoate, acetate, and lactate can serve as
574 energy sources for cells by converting into acetyl-CoA, which can then be utilized in the
575 tricarboxylic acid (TCA) cycle to produce ATP.¹²⁷⁻¹³⁰ The role of butanoate in tumorigenesis

576 depends on the specific tumour and the TME, as it can exhibit tumour-promoting or
577 suppressive properties.^{31, 131-133} Lactate, a well-studied metabolite produced by both cancer
578 cells and bacteria, can modulate the TME by inactivating natural killer cells, promoting
579 polarisation of M2-like tumour-associated macrophages, and stimulating the growth of T-
580 regulatory cells.¹³⁴ Collectively, these findings suggest that bacteria infiltrating HNSC tissues
581 possess functional capacities that may promote cancer progression. Further validation studies
582 are warranted to better understand the role of these metabolic pathways in HNSC and the
583 contribution of bacteria in shaping the TME.

584

585 We further explored the relationship between the abundance of the five cancer-associated
586 bacterial genera, *Fusobacterium*, *Selenomonas*, *Treponema*, *Actinomyces*, and *Rothia*, and the
587 TME phenotype and clinical outcomes. *Fusobacterium* was associated with a lack of T-cell
588 immune infiltration in HNSC, similar to colorectal and oesophageal cancers.^{21, 135-137}
589 Furthermore, *Fusobacterium* can chemoattract neutrophils via release of SCFA and can also
590 modulate neutrophils and endothelial cell functions *in vitro*.¹³⁸⁻¹⁴² Interestingly, we observed
591 that patients with low levels of *Fusobacterium* within the tumour tissue had shorter overall
592 survival, consistent to previous reports in HNSC.^{45, 60, 143} In contrast, opposite findings have
593 been reported for colorectal, gastric and oesophageal cancers, suggesting that *Fusobacterium*
594 may have a different role in HNSC.¹⁴⁴⁻¹⁴⁷ We also found that *Treponema* correlated with an
595 lack of immune infiltration in HNSC. Although the effect of *Treponema* infiltration in HNSC
596 is still unknown, these bacteria have been associated with an upregulation of immune
597 suppressive cells and can suppress innate immune responses.¹⁴⁸⁻¹⁵⁰ In our analysis, *Rothia*
598 was found to correlate with an immune-enriched TME. Limited information is available
599 regarding the role of *Rothia* in cancer; however, *Rothia dentocariosa* has been shown to
600 induce Toll-like receptor 2 (TLR-2) mediated TNF-alpha inflammatory response in human

601 embryonic kidney cells and THP-1 monocytes.¹⁵¹ *Selenomonas* and *Actinomyces* did not
602 significantly correlate with TME subtypes in our analysis. However, *Selenomonas sputigena*
603 infected gingival epithelial cells can promote neutrophil and monocyte recruitment.¹⁵²
604 *Actinomyces* has been associated with young-onset colorectal cancers, showing a preferential
605 localisation with cancer-associated fibroblasts in the TME.¹⁵³ These findings underscore the
606 importance of validating and understanding the underlying mechanisms through which these
607 bacteria can modulate the tumour microenvironment in HNSC.

608

609 This study represents the first comprehensive comparison of 16S rRNA (V3-V5) microbial
610 sequencing across multiple studies to identify consensus HNSC-associated microbiota
611 signatures in cancer, cancer-adjacent and non-cancer tissues. To ensure consistency, a
612 uniform bioinformatics approach was employed. However, it is important to acknowledge the
613 inherent limitations of this study. Variations in sample collection, preparation, and
614 sequencing among different laboratories introduce batch effects that could contribute to the
615 inconsistencies observed across different reports. To mitigate these effects, we applied
616 PLSDA-batch adjustment to the pooled datasets.⁹¹ Conventional short-read 16S rRNA
617 sequencing provides information only up to the genus level, which restricts the ability to
618 identify specific bacterial species or strains that may be relevant to disease outcomes.¹²¹
619 Overcoming this limitation would require advanced sequencing technologies such as long-
620 read 16S rRNA amplicon sequencing or shotgun metagenomics to reveal species- or strain-
621 level diversity within the microbiota. Furthermore, the availability of complete clinical
622 metadata in published datasets reporting 16S rRNA sequencing is limited, restricting our
623 ability to make comprehensive clinical associations. Therefore, our clinical associations were
624 primarily based on TCMA/TCGA datasets. Despite these limitations, this study confirms
625 distinct differences in the microbiota composition among cancer, cancer-adjacent and non-

626 cancer HNSC tissue samples. The strength of our study lies in the meta-analysis of a
627 substantial number of samples, totalling 903. Additionally, our analysis indicates that a high
628 load of *Fusobacterium* within HNSC tissues may be associated with a favourable survival
629 outcome. The correlation analysis of the microbiota with functional predictions, functional
630 gene enrichment signature, and immune subtyping of the tumour and TME provides novel
631 avenues for further exploration.

632

633 In conclusion, our study establishes a consensus microbial signature for head and neck
634 tissues, shedding light on the distinct microbial profiles present in head and neck cancer
635 (HNSC). These findings have the potential to serve as targets for future treatment approaches
636 in HNSC. Nevertheless, it is crucial to acknowledge the limitations identified in our study
637 and recognize the need for further research to address these limitations. Additional
638 investigations are required to gain a deeper understanding of the functional implications of
639 the identified microbiota differences in HNSC. By addressing these gaps, we can advance our
640 knowledge and pave the way for more effective therapeutic interventions in HNSC.

641

642 **5. Conflict of Interest**

643 Authors state no conflict of interest.

644

645 **6. Author Contributions**

646 Conceptualisation K.Y.,K.F.; methodology, investigation, and data analysis, K.Y.,R.L.,F.W.,
647 E.S., G.B., and L.M.; resources A.P.,P.W. and S.V.; writing - original draft preparation, K.Y.,
648 E.S., S.V., and K.F; writing-review and editing, K.Y., G.B., E.S., A.P., P.W., R.V., S.V., and
649 K.F.; supervision R.V.,A.P., S.V., and K.F.; funding acquisition, A.P.,P.W., and S.V.; All
650 authors have read and agreed to the published version of the manuscript.

651 **7. Acknowledgments**

652 This work is supported by an NHMRC investigator grant APP1196832 to P.W., a The
653 Garnett Passe and Rodney Williams Senior Fellowship to S.V., and The University of
654 Adelaide Postgraduate Research Scholarship to K.Y., R.L., F.W and L.M. Illustration in
655 Figure 6 was generated using Biorender.

656

657 **8. Data Availability Statement**

658 The data used to support the findings of this study are included within the article and within
659 supplementary material.

660 **Reference:**

- 661 1. Dohlman AB, Arguijo Mendoza D, Ding S, et al. The cancer microbiome atlas: a pan-
662 cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. *Cell*
663 *Host Microbe*. Feb 10 2021;29(2):281-298.e5. doi:10.1016/j.chom.2020.12.001
- 664 2. Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of
665 tumor type-specific intracellular bacteria. *Science*. May 29 2020;368(6494):973-980.
666 doi:10.1126/science.aay9189
- 667 3. Xuan C, Shamonki JM, Chung A, et al. Microbial dysbiosis is associated with human
668 breast cancer. *PLoS One*. 2014;9(1):e83744. doi:10.1371/journal.pone.0083744
- 669 4. Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer-
670 Microbiome-Immune Axis: Decrypting a Decade of Discoveries. *Front Immunol*.
671 2021;12:622064. doi:10.3389/fimmu.2021.622064
- 672 5. Xavier JB, Young VB, Skufca J, et al. The Cancer Microbiome: Distinguishing Direct
673 and Indirect Effects Requires a Systemic View. *Trends Cancer*. Mar 2020;6(3):192-204.
674 doi:10.1016/j.trecan.2020.01.004
- 675 6. Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation,
676 development and therapeutic efficacy. *Signal Transduct Target Ther*. Jan 16 2023;8(1):35.
677 doi:10.1038/s41392-022-01304-4
- 678 7. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4
679 blockade relies on the gut microbiota. *Science*. Nov 27 2015;350(6264):1079-84.
680 doi:10.1126/science.aad1329
- 681 8. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes
682 antitumor immunity and facilitates anti-PD-L1 efficacy. *Science*. Nov 27
683 2015;350(6264):1084-9. doi:10.1126/science.aac4255
- 684 9. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to
685 therapy by modulating the tumor microenvironment. *Science*. Nov 22 2013;342(6161):967-
686 70. doi:10.1126/science.1240527
- 687 10. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the
688 anticancer immune effects of cyclophosphamide. *Science*. Nov 22 2013;342(6161):971-6.
689 doi:10.1126/science.1240537
- 690 11. Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes
691 metastatic colonization in breast cancer. *Cell*. Apr 14 2022;185(8):1356-1372.e26.
692 doi:10.1016/j.cell.2022.02.027
- 693 12. Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in
694 mediating tumor resistance to the chemotherapeutic drug gemcitabine. *Science*. Sep 15
695 2017;357(6356):1156-1160. doi:10.1126/science.aah5043
- 696 13. Yu T, Guo F, Yu Y, et al. *Fusobacterium nucleatum* Promotes Chemoresistance to
697 Colorectal Cancer by Modulating Autophagy. *Cell*. Jul 27 2017;170(3):548-563.e16.
698 doi:10.1016/j.cell.2017.07.008
- 699 14. Spanogiannopoulos P, Kyaw TS, Guthrie BGH, et al. Host and gut bacteria share
700 metabolic pathways for anti-cancer drug metabolism. *Nat Microbiol*. Oct 2022;7(10):1605-
701 1620. doi:10.1038/s41564-022-01226-5
- 702 15. Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of *Fusobacterium*
703 *nucleatum* to human inhibitory receptor TIGIT protects tumors from immune cell attack.
704 *Immunity*. Feb 17 2015;42(2):344-355. doi:10.1016/j.immuni.2015.01.010
- 705 16. Kalaora S, Nagler A, Nejman D, et al. Identification of bacteria-derived HLA-bound
706 peptides in melanoma. *Nature*. Apr 2021;592(7852):138-143. doi:10.1038/s41586-021-
707 03368-8

- 708 17. Naghavian R, Faigle W, Oldrati P, et al. Microbial peptides activate tumour-
709 infiltrating lymphocytes in glioblastoma. *Nature*. May 2023;617(7962):807-817.
710 doi:10.1038/s41586-023-06081-w
- 711 18. Abed J, Emgård JE, Zamir G, et al. Fap2 Mediates *Fusobacterium nucleatum*
712 Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. *Cell*
713 *Host Microbe*. Aug 10 2016;20(2):215-25. doi:10.1016/j.chom.2016.07.006
- 714 19. Parhi L, Alon-Maimon T, Sol A, et al. Breast cancer colonization by *Fusobacterium*
715 *nucleatum* accelerates tumor growth and metastatic progression. *Nat Commun*. Jun 26
716 2020;11(1):3259. doi:10.1038/s41467-020-16967-2
- 717 20. Zhang S, Yang Y, Weng W, et al. *Fusobacterium nucleatum* promotes
718 chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
719 *J Exp Clin Cancer Res*. Jan 10 2019;38(1):14. doi:10.1186/s13046-018-0985-y
- 720 21. Wu J, Li Q, Fu X. *Fusobacterium nucleatum* Contributes to the Carcinogenesis of
721 Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity. *Transl Oncol*.
722 Jun 2019;12(6):846-851. doi:10.1016/j.tranon.2019.03.003
- 723 22. Gur C, Maalouf N, Shhadeh A, et al. *Fusobacterium nucleatum* suppresses anti-tumor
724 immunity by activating CEACAM1. *Oncoimmunology*. 2019;8(6):e1581531.
725 doi:10.1080/2162402x.2019.1581531
- 726 23. Yoon Y, Kim G, Jeon BN, Fang S, Park H. *Bifidobacterium* Strain-Specific Enhances
727 the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. *Cancers (Basel)*. Feb 25
728 2021;13(5)doi:10.3390/cancers13050957
- 729 24. Asadollahi P, Ghanavati R, Rohani M, Razavi S, Esghaei M, Talebi M. Anti-cancer
730 effects of *Bifidobacterium* species in colon cancer cells and a mouse model of carcinogenesis.
731 *PLoS One*. 2020;15(5):e0232930. doi:10.1371/journal.pone.0232930
- 732 25. Rossi T, Vergara D, Fanini F, Maffia M, Bravaccini S, Pirini F. Microbiota-Derived
733 Metabolites in Tumor Progression and Metastasis. *Int J Mol Sci*. Aug 12
734 2020;21(16)doi:10.3390/ijms21165786
- 735 26. Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom
736 intermediates. *Nat Rev Microbiol*. Feb 2021;19(2):77-94. doi:10.1038/s41579-020-0438-4
- 737 27. Bachem A, Makhlof C, Binger KJ, et al. Microbiota-Derived Short-Chain Fatty
738 Acids Promote the Memory Potential of Antigen-Activated CD8(+) T Cells. *Immunity*. Aug
739 20 2019;51(2):285-297.e5. doi:10.1016/j.immuni.2019.06.002
- 740 28. Wang W, Fang D, Zhang H, et al. Sodium Butyrate Selectively Kills Cancer Cells and
741 Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1. *Onco Targets Ther*.
742 2020;13:4691-4704. doi:10.2147/ott.S235575
- 743 29. Liang Y, Rao Z, Du D, Wang Y, Fang T. Butyrate prevents the migration and
744 invasion, and aerobic glycolysis in gastric cancer via inhibiting Wnt/ β -catenin/c-Myc
745 signaling. *Drug Dev Res*. May 2023;84(3):532-541. doi:10.1002/ddr.22043
- 746 30. He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy
747 efficacy by modulating cytotoxic CD8(+) T cell immunity. *Cell Metab*. May 4
748 2021;33(5):988-1000.e7. doi:10.1016/j.cmet.2021.03.002
- 749 31. Okumura S, Konishi Y, Narukawa M, et al. Gut bacteria identified in colorectal
750 cancer patients promote tumorigenesis via butyrate secretion. *Nat Commun*. Sep 28
751 2021;12(1):5674. doi:10.1038/s41467-021-25965-x
- 752 32. Zaiatz-Bittencourt V, Jones F, Tosetto M, et al. Butyrate limits human natural killer
753 cell effector function. *Sci Rep*. Feb 15 2023;13(1):2715. doi:10.1038/s41598-023-29731-5
- 754 33. Bender MJ, McPherson AC, Phelps CM, et al. Dietary tryptophan metabolite released
755 by intratumoral *Lactobacillus reuteri* facilitates immune checkpoint inhibitor treatment. *Cell*.
756 Apr 27 2023;186(9):1846-1862.e26. doi:10.1016/j.cell.2023.03.011

- 757 34. Tintelnot J, Xu Y, Lesker TR, et al. Microbiota-derived 3-IAA influences
758 chemotherapy efficacy in pancreatic cancer. *Nature*. Mar 2023;615(7950):168-174.
759 doi:10.1038/s41586-023-05728-y
- 760 35. Hezaveh K, Shinde RS, Klötgen A, et al. Tryptophan-derived microbial metabolites
761 activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-
762 tumor immunity. *Immunity*. Feb 8 2022;55(2):324-340.e8. doi:10.1016/j.immuni.2022.01.006
- 763 36. Chang C, Geng F, Shi X, et al. The prevalence rate of periodontal pathogens and its
764 association with oral squamous cell carcinoma. *Appl Microbiol Biotechnol*. Feb
765 2019;103(3):1393-1404. doi:10.1007/s00253-018-9475-6
- 766 37. Zhou J, Wang L, Yuan R, et al. Signatures of Mucosal Microbiome in Oral Squamous
767 Cell Carcinoma Identified Using a Random Forest Model. *Cancer Manag Res*.
768 2020;12:5353-5363. doi:10.2147/cmar.S251021
- 769 38. Torralba MG, Aleti G, Li W, et al. Oral Microbial Species and Virulence Factors
770 Associated with Oral Squamous Cell Carcinoma. *Microb Ecol*. Nov 2021;82(4):1030-1046.
771 doi:10.1007/s00248-020-01596-5
- 772 39. Henrich B, Rumming M, Sczyrba A, et al. Mycoplasma salivarium as a dominant
773 coloniser of Fanconi anaemia associated oral carcinoma. *PLoS One*. 2014;9(3):e92297.
774 doi:10.1371/journal.pone.0092297
- 775 40. Chan JYK, Ng CWK, Lan L, et al. Restoration of the Oral Microbiota After Surgery
776 for Head and Neck Squamous Cell Carcinoma Is Associated With Patient Outcomes. *Front*
777 *Oncol*. 2021;11:737843. doi:10.3389/fonc.2021.737843
- 778 41. De Martin A, Lütge M, Stanossek Y, et al. Distinct microbial communities colonize
779 tonsillar squamous cell carcinoma. *Oncoimmunology*. 2021;10(1):1945202.
780 doi:10.1080/2162402x.2021.1945202
- 781 42. Zakrzewski M, Gannon OM, Panizza BJ, Saunders NA, Antonsson A. Human
782 papillomavirus infection and tumor microenvironment are associated with the microbiota in
783 patients with oropharyngeal cancers-pilot study. *Head Neck*. Nov 2021;43(11):3324-3330.
784 doi:10.1002/hed.26821
- 785 43. Sarkar P, Malik S, Laha S, et al. Dysbiosis of Oral Microbiota During Oral Squamous
786 Cell Carcinoma Development. *Front Oncol*. 2021;11:614448. doi:10.3389/fonc.2021.614448
- 787 44. Zhou X, Hao Y, Peng X, et al. The Clinical Potential of Oral Microbiota as a
788 Screening Tool for Oral Squamous Cell Carcinomas. *Front Cell Infect Microbiol*.
789 2021;11:728933. doi:10.3389/fcimb.2021.728933
- 790 45. Chen Z, Wong PY, Ng CWK, et al. The Intersection between Oral Microbiota, Host
791 Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma.
792 *Cancers (Basel)*. Nov 18 2020;12(11)doi:10.3390/cancers12113425
- 793 46. Perera M, Al-Hebshi NN, Perera I, et al. Inflammatory Bacteriome and Oral
794 Squamous Cell Carcinoma. *J Dent Res*. Jun 2018;97(6):725-732.
795 doi:10.1177/0022034518767118
- 796 47. Al-Hebshi NN, Nasher AT, Maryoud MY, et al. Inflammatory bacteriome featuring
797 *Fusobacterium nucleatum* and *Pseudomonas aeruginosa* identified in association with oral
798 squamous cell carcinoma. *Sci Rep*. May 12 2017;7(1):1834. doi:10.1038/s41598-017-02079-
799 3
- 800 48. Schmidt BL, Kuczynski J, Bhattacharya A, et al. Changes in abundance of oral
801 microbiota associated with oral cancer. *PLoS One*. 2014;9(6):e98741.
802 doi:10.1371/journal.pone.0098741
- 803 49. Wang H, Funchain P, Bebek G, et al. Microbiomic differences in tumor and paired-
804 normal tissue in head and neck squamous cell carcinomas. *Genome Med*. Feb 7 2017;9(1):14.
805 doi:10.1186/s13073-017-0405-5

- 806 50. Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, et al. 16S rRNA amplicon
807 sequencing identifies microbiota associated with oral cancer, human papilloma virus
808 infection and surgical treatment. *Oncotarget*. Aug 9 2016;7(32):51320-51334.
809 doi:10.18632/oncotarget.9710
- 810 51. Gong H, Shi Y, Zhou X, et al. Microbiota in the Throat and Risk Factors for
811 Laryngeal Carcinoma. *Appl Environ Microbiol*. Dec 2014;80(23):7356-63.
812 doi:10.1128/aem.02329-14
- 813 52. Gong HL, Shi Y, Zhou L, et al. The Composition of Microbiome in Larynx and the
814 Throat Biodiversity between Laryngeal Squamous Cell Carcinoma Patients and Control
815 Population. *PLoS One*. 2013;8(6):e66476. doi:10.1371/journal.pone.0066476
- 816 53. Pushalkar S, Ji X, Li Y, et al. Comparison of oral microbiota in tumor and non-tumor
817 tissues of patients with oral squamous cell carcinoma. *BMC Microbiol*. Jul 20 2012;12:144.
818 doi:10.1186/1471-2180-12-144
- 819 54. Burcher KM, Burcher JT, Inscore L, Bloomer CH, Furdui CM, Porosnicu M. A
820 Review of the Role of Oral Microbiome in the Development, Detection, and Management of
821 Head and Neck Squamous Cell Cancers. *Cancers (Basel)*. Aug 25
822 2022;14(17)doi:10.3390/cancers14174116
- 823 55. Yang K, Wang Y, Zhang S, et al. Oral Microbiota Analysis of Tissue Pairs and Saliva
824 Samples From Patients With Oral Squamous Cell Carcinoma - A Pilot Study. *Front*
825 *Microbiol*. 2021;12:719601. doi:10.3389/fmicb.2021.719601
- 826 56. Gopinath D, Kunnath Menon R, Chun Wie C, et al. Salivary bacterial shifts in oral
827 leukoplakia resemble the dysbiotic oral cancer bacteriome. *J Oral Microbiol*. Dec 9
828 2020;13(1):1857998. doi:10.1080/20002297.2020.1857998
- 829 57. Gong H, Shi Y, Xiao X, et al. Alterations of microbiota structure in the larynx
830 relevant to laryngeal carcinoma. *Sci Rep*. Jul 14 2017;7(1):5507. doi:10.1038/s41598-017-
831 05576-7
- 832 58. Dong Z, Zhang C, Zhao Q, et al. Alterations of bacterial communities of vocal cord
833 mucous membrane increases the risk for glottic laryngeal squamous cell carcinoma. *J*
834 *Cancer*. 2021;12(13):4049-4063. doi:10.7150/jca.54221
- 835 59. Shin JM, Luo T, Kamarajan P, Fenno JC, Rickard AH, Kapila YL. Microbial
836 Communities Associated with Primary and Metastatic Head and Neck Squamous Cell
837 Carcinoma - A High Fusobacterial and Low Streptococcal Signature. *Sci Rep*. Aug 30
838 2017;7(1):9934. doi:10.1038/s41598-017-09786-x
- 839 60. Chan JYK, Cheung MK, Lan L, et al. Characterization of oral microbiota in HPV and
840 non-HPV head and neck squamous cell carcinoma and its association with patient outcomes.
841 *Oral Oncol*. Dec 2022;135:106245. doi:10.1016/j.oraloncology.2022.106245
- 842 61. Choi YS, Kim Y, Yoon HJ, et al. The presence of bacteria within tissue provides
843 insights into the pathogenesis of oral lichen planus. *Sci Rep*. Jul 7 2016;6:29186.
844 doi:10.1038/srep29186
- 845 62. Baek K, Lee J, Lee A, et al. Characterization of intratissue bacterial communities and
846 isolation of *Escherichia coli* from oral lichen planus lesions. *Sci Rep*. Feb 26
847 2020;10(1):3495. doi:10.1038/s41598-020-60449-w
- 848 63. Bao K, Li X, Poveda L, et al. Proteome and Microbiome Mapping of Human Gingival
849 Tissue in Health and Disease. *Front Cell Infect Microbiol*. 2020;10:588155.
850 doi:10.3389/fcimb.2020.588155
- 851 64. Sawant S, Dugad J, Parikh D, Srinivasan S, Singh H. Identification & correlation of
852 bacterial diversity in oral cancer and long-term tobacco chewers- A case-control pilot study. *J*
853 *Med Microbiol*. Sep 2021;70(9)doi:10.1099/jmm.0.001417

- 854 65. Frank DN, Qiu Y, Cao Y, et al. A dysbiotic microbiome promotes head and neck
855 squamous cell carcinoma. *Oncogene*. Feb 2022;41(9):1269-1280. doi:10.1038/s41388-021-
856 02137-1
- 857 66. Sharma AK, DeBusk WT, Stepanov I, Gomez A, Khariwala SS. Oral Microbiome
858 Profiling in Smokers with and without Head and Neck Cancer Reveals Variations Between
859 Health and Disease. *Cancer Prev Res (Phila)*. May 2020;13(5):463-474. doi:10.1158/1940-
860 6207.Capr-19-0459
- 861 67. Lau HC, Hsueh CY, Gong H, et al. Oropharynx microbiota transitions in
862 hypopharyngeal carcinoma treatment of induced chemotherapy followed by surgery. *BMC*
863 *Microbiol*. Nov 9 2021;21(1):310. doi:10.1186/s12866-021-02362-4
- 864 68. Hsueh CY, Gong H, Cong N, et al. Throat Microbial Community Structure and
865 Functional Changes in Postsurgery Laryngeal Carcinoma Patients. *Appl Environ Microbiol*.
866 Nov 24 2020;86(24)doi:10.1128/aem.01849-20
- 867 69. Panda M, Rai AK, Rahman T, et al. Alterations of salivary microbial community
868 associated with oropharyngeal and hypopharyngeal squamous cell carcinoma patients. *Arch*
869 *Microbiol*. May 2020;202(4):785-805. doi:10.1007/s00203-019-01790-1
- 870 70. Vesty A, Gear K, Biswas K, Radcliff FJ, Taylor MW, Douglas RG. Microbial and
871 inflammatory-based salivary biomarkers of head and neck squamous cell carcinoma. *Clin*
872 *Exp Dent Res*. Dec 2018;4(6):255-262. doi:10.1002/cre2.139
- 873 71. Lee WH, Chen HM, Yang SF, et al. Bacterial alterations in salivary microbiota and
874 their association in oral cancer. *Sci Rep*. Nov 28 2017;7(1):16540. doi:10.1038/s41598-017-
875 16418-x
- 876 72. Amer A, Galvin S, Healy CM, Moran GP. The Microbiome of Potentially Malignant
877 Oral Leukoplakia Exhibits Enrichment for Fusobacterium, Leptotrichia, Campylobacter, and
878 Rothia Species. *Front Microbiol*. 2017;8:2391. doi:10.3389/fmicb.2017.02391
- 879 73. Chen MY, Chen JW, Wu LW, et al. Carcinogenesis of Male Oral Submucous Fibrosis
880 Alters Salivary Microbiomes. *J Dent Res*. Apr 2021;100(4):397-405.
881 doi:10.1177/0022034520968750
- 882 74. Debelius JW, Huang T, Cai Y, et al. Subspecies Niche Specialization in the Oral
883 Microbiome Is Associated with Nasopharyngeal Carcinoma Risk. *mSystems*. Jul 7
884 2020;5(4)doi:10.1128/mSystems.00065-20
- 885 75. Kumpitsch C, Moissl-Eichinger C, Pock J, Thurnher D, Wolf A. Preliminary insights
886 into the impact of primary radiochemotherapy on the salivary microbiome in head and neck
887 squamous cell carcinoma. *Sci Rep*. Oct 6 2020;10(1):16582. doi:10.1038/s41598-020-73515-
888 0
- 889 76. Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV, Thurnher D. The
890 salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal
891 squamous cell carcinoma: A pilot study. *Sci Rep*. Jul 19 2017;7(1):5867. doi:10.1038/s41598-
892 017-06361-2
- 893 77. Zhu XX, Yang XJ, Chao YL, et al. The Potential Effect of Oral Microbiota in the
894 Prediction of Mucositis During Radiotherapy for Nasopharyngeal Carcinoma. *EBioMedicine*.
895 Apr 2017;18:23-31. doi:10.1016/j.ebiom.2017.02.002
- 896 78. Furquim CP, Soares GM, Ribeiro LL, et al. The Salivary Microbiome and Oral
897 Cancer Risk: a Pilot Study in Fanconi Anemia. *J Dent Res*. Mar 2017;96(3):292-299.
898 doi:10.1177/0022034516678169
- 899 79. Zhang J, Liu H, Liang X, et al. Investigation of salivary function and oral microbiota
900 of radiation caries-free people with nasopharyngeal carcinoma. *PLoS One*.
901 2015;10(4):e0123137. doi:10.1371/journal.pone.0123137

- 902 80. Hu YJ, Wang Q, Jiang YT, et al. Characterization of oral bacterial diversity of
903 irradiated patients by high-throughput sequencing. *Int J Oral Sci*. Mar 2013;5(1):21-5.
904 doi:10.1038/ijos.2013.15
- 905 81. Pushalkar S, Mane SP, Ji X, et al. Microbial diversity in saliva of oral squamous cell
906 carcinoma. *FEMS Immunol Med Microbiol*. Apr 2011;61(3):269-77. doi:10.1111/j.1574-
907 695X.2010.00773.x
- 908 82. Hu YJ, Shao ZY, Wang Q, et al. Exploring the dynamic core microbiome of plaque
909 microbiota during head-and-neck radiotherapy using pyrosequencing. *PLoS One*.
910 2013;8(2):e56343. doi:10.1371/journal.pone.0056343
- 911 83. Minarovits J. Anaerobic bacterial communities associated with oral carcinoma:
912 Intratumoral, surface-biofilm and salivary microbiota. *Anaerobe*. Apr 2021;68:102300.
913 doi:10.1016/j.anaerobe.2020.102300
- 914 84. Orlandi E, Iacovelli NA, Tombolini V, et al. Potential role of microbiome in
915 oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. *Oral*
916 *Oncol*. Dec 2019;99:104453. doi:10.1016/j.oraloncology.2019.104453
- 917 85. Gopinath D, Menon RK, Wie CC, et al. Differences in the bacteriome of swab, saliva,
918 and tissue biopsies in oral cancer. *Sci Rep*. Jan 13 2021;11(1):1181. doi:10.1038/s41598-020-
919 80859-0
- 920 86. Jain V, Baraniya D, El-Hadedy DE, et al. Integrative Metatranscriptomic Analysis
921 Reveals Disease-specific Microbiome–host Interactions in Oral Squamous Cell Carcinoma.
922 *Cancer Res Commun*. 2023;3(5):807-820. doi:10.1158/2767-9764.CRC-22-0349
- 923 87. Wang X, Zhao Z, Tang N, et al. Microbial Community Analysis of Saliva and
924 Biopsies in Patients With Oral Lichen Planus. *Front Microbiol*. 2020;11:629.
925 doi:10.3389/fmicb.2020.00629
- 926 88. Zhang Z, Feng Q, Li M, et al. Age-Related Cancer-Associated Microbiota Potentially
927 Promotes Oral Squamous Cell Cancer Tumorigenesis by Distinct Mechanisms. *Front*
928 *Microbiol*. 2022;13:852566. doi:10.3389/fmicb.2022.852566
- 929 89. Nie F, Wang L, Huang Y, et al. Characteristics of Microbial Distribution in Different
930 Oral Niches of Oral Squamous Cell Carcinoma. *Front Cell Infect Microbiol*.
931 2022;12:905653. doi:10.3389/fcimb.2022.905653
- 932 90. Qiao H, Li H, Wen X, Tan X, Yang C, Liu N. Multi-Omics Integration Reveals the
933 Crucial Role of Fusobacterium in the Inflammatory Immune Microenvironment in Head and
934 Neck Squamous Cell Carcinoma. *Microbiol Spectr*. Aug 31 2022;10(4):e0106822.
935 doi:10.1128/spectrum.01068-22
- 936 91. Wang Y, KA LC. PLSDA-batch: a multivariate framework to correct for batch effects
937 in microbiome data. *Brief Bioinform*. Mar 19 2023;24(2)doi:10.1093/bib/bbac622
- 938 92. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated
939 guideline for reporting systematic reviews. *Rev Esp Cardiol (Engl Ed)*. Sep 2021;74(9):790-
940 799. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones
941 sistemáticas. doi:10.1016/j.rec.2021.07.010
- 942 93. Choudhary S. pysradb: A Python package to query next-generation sequencing
943 metadata and data from NCBI Sequence Read Archive. *F1000Res*. 2019;8:532.
944 doi:10.12688/f1000research.18676.1
- 945 94. Leinonen R, Sugawara H, Shumway M. The sequence read archive. *Nucleic Acids*
946 *Res*. Jan 2011;39(Database issue):D19-21. doi:10.1093/nar/gkq1019
- 947 95. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and
948 extensible microbiome data science using QIIME 2. *Nat Biotechnol*. Aug 2019;37(8):852-
949 857. doi:10.1038/s41587-019-0209-9

- 950 96. Rohart F, Gautier B, Singh A, KA LC. mixOmics: An R package for 'omics feature
951 selection and multiple data integration. *PLoS Comput Biol*. Nov 2017;13(11):e1005752.
952 doi:10.1371/journal.pcbi.1005752
- 953 97. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis
954 and graphics of microbiome census data. *PLoS One*. 2013;8(4):e61217.
955 doi:10.1371/journal.pone.0061217
- 956 98. Moentadj R, Wang Y, Bowerman K, et al. Streptococcus species enriched in the oral
957 cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can
958 induce arthritis in mice. *Ann Rheum Dis*. May 2021;80(5):573-581.
959 doi:10.1136/annrheumdis-2020-219009
- 960 99. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets
961 Are Compositional: And This Is Not Optional. *Front Microbiol*. 2017;8:2224.
962 doi:10.3389/fmicb.2017.02224
- 963 100. Khomich M, Måge I, Rud I, Berget I. Analysing microbiome intervention design
964 studies: Comparison of alternative multivariate statistical methods. *PLoS One*.
965 2021;16(11):e0259973. doi:10.1371/journal.pone.0259973
- 966 101. Cao Y, Dong Q, Wang D, Zhang P, Liu Y, Niu C. microbiomeMarker: an
967 R/Bioconductor package for microbiome marker identification and visualization.
968 *Bioinformatics*. Aug 10 2022;38(16):4027-4029. doi:10.1093/bioinformatics/btac438
- 969 102. Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome
970 functions. *Nat Biotechnol*. Jun 2020;38(6):685-688. doi:10.1038/s41587-020-0548-6
- 971 103. Caspi R, Billington R, Keseler IM, et al. The MetaCyc database of metabolic
972 pathways and enzymes - a 2019 update. *Nucleic Acids Res*. Jan 8 2020;48(D1):D445-d453.
973 doi:10.1093/nar/gkz862
- 974 104. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer
975 genomics and clinical profiles using the cBioPortal. *Sci Signal*. Apr 2 2013;6(269):p11.
976 doi:10.1126/scisignal.2004088
- 977 105. Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment
978 subtypes predict response to immunotherapy. *Cancer Cell*. Jun 14 2021;39(6):845-865.e7.
979 doi:10.1016/j.ccell.2021.04.014
- 980 106. Eren AM, Borisy GG, Huse SM, Mark Welch JL. Oligotyping analysis of the human
981 oral microbiome. *Proc Natl Acad Sci U S A*. Jul 15 2014;111(28):E2875-84.
982 doi:10.1073/pnas.1409644111
- 983 107. Mark Welch JL, Rossetti BJ, Rieken CW, Dewhirst FE, Borisy GG. Biogeography of
984 a human oral microbiome at the micron scale. *Proc Natl Acad Sci U S A*. Feb 9
985 2016;113(6):E791-800. doi:10.1073/pnas.1522149113
- 986 108. Wilbert SA, Mark Welch JL, Borisy GG. Spatial Ecology of the Human Tongue
987 Dorsum Microbiome. *Cell Rep*. Mar 24 2020;30(12):4003-4015.e3.
988 doi:10.1016/j.celrep.2020.02.097
- 989 109. Shao W, Fujiwara N, Mouri Y, et al. Conversion from epithelial to partial-EMT
990 phenotype by *Fusobacterium nucleatum* infection promotes invasion of oral cancer cells. *Sci*
991 *Rep*. Jul 22 2021;11(1):14943. doi:10.1038/s41598-021-94384-1
- 992 110. Chen G, Gao C, Jiang S, et al. *Fusobacterium nucleatum* outer membrane vesicles
993 activate autophagy to promote oral cancer metastasis. *J Adv Res*. Apr 13
994 2023;doi:10.1016/j.jare.2023.04.002
- 995 111. Geng F, Zhang Y, Lu Z, Zhang S, Pan Y. *Fusobacterium nucleatum* Caused DNA
996 Damage and Promoted Cell Proliferation by the Ku70/p53 Pathway in Oral Cancer Cells.
997 *DNA Cell Biol*. Jan 2020;39(1):144-151. doi:10.1089/dna.2019.5064
- 998 112. Zhang S, Li C, Liu J, et al. *Fusobacterium nucleatum* promotes epithelial-
999 mesenchymal transition through regulation of the lncRNA MIR4435-2HG/miR-296-

- 1000 5p/Akt2/SNAI1 signaling pathway. *Febs j.* Sep 2020;287(18):4032-4047.
1001 doi:10.1111/febs.15233
- 1002 113. Binder Gallimidi A, Fischman S, Revach B, et al. Periodontal pathogens
1003 *Porphyromonas gingivalis* and *Fusobacterium nucleatum* promote tumor progression in an
1004 oral-specific chemical carcinogenesis model. *Oncotarget.* Sep 8 2015;6(26):22613-23.
1005 doi:10.18632/oncotarget.4209
- 1006 114. Baty JJ, Stoner SN, Scofield JA. Oral Commensal Streptococci: Gatekeepers of the
1007 Oral Cavity. *J Bacteriol.* Nov 15 2022;204(11):e0025722. doi:10.1128/jb.00257-22
- 1008 115. Tsai MS, Chen YY, Chen WC, Chen MF. Streptococcus mutans promotes tumor
1009 progression in oral squamous cell carcinoma. *J Cancer.* 2022;13(12):3358-3367.
1010 doi:10.7150/jca.73310
- 1011 116. Baraniya D, Jain V, Lucarelli R, et al. Screening of Health-Associated Oral Bacteria
1012 for Anticancer Properties in vitro. *Front Cell Infect Microbiol.* 2020;10:575656.
1013 doi:10.3389/fcimb.2020.575656
- 1014 117. Xu Y, Jia Y, Chen L, Gao J, Yang D. Effect of Streptococcus anginosus on biological
1015 response of tongue squamous cell carcinoma cells. *BMC Oral Health.* Mar 20
1016 2021;21(1):141. doi:10.1186/s12903-021-01505-3
- 1017 118. Baraniya D, Chitralla KN, Al-Hebshi NN. Global transcriptional response of oral
1018 squamous cell carcinoma cell lines to health-associated oral bacteria - an in vitro study. *J*
1019 *Oral Microbiol.* 2022;14(1):2073866. doi:10.1080/20002297.2022.2073866
- 1020 119. Wang J, Sun F, Lin X, Li Z, Mao X, Jiang C. Cytotoxic T cell responses to
1021 Streptococcus are associated with improved prognosis of oral squamous cell carcinoma. *Exp*
1022 *Cell Res.* Jan 1 2018;362(1):203-208. doi:10.1016/j.yexcr.2017.11.018
- 1023 120. Wang J, Yang L, Mao X, Li Z, Lin X, Jiang C. Streptococcus salivarius-mediated
1024 CD8(+) T cell stimulation required antigen presentation by macrophages in oral squamous
1025 cell carcinoma. *Exp Cell Res.* May 15 2018;366(2):121-126. doi:10.1016/j.yexcr.2018.03.007
- 1026 121. Curry KD, Wang Q, Nute MG, et al. Emu: species-level microbial community
1027 profiling of full-length 16S rRNA Oxford Nanopore sequencing data. *Nat Methods.* Jul
1028 2022;19(7):845-853. doi:10.1038/s41592-022-01520-4
- 1029 122. Johnson JS, Spakowicz DJ, Hong BY, et al. Evaluation of 16S rRNA gene sequencing
1030 for species and strain-level microbiome analysis. *Nat Commun.* Nov 6 2019;10(1):5029.
1031 doi:10.1038/s41467-019-13036-1
- 1032 123. Gehrig JL, Portik DM, Driscoll MD, et al. Finding the right fit: evaluation of short-
1033 read and long-read sequencing approaches to maximize the utility of clinical microbiome
1034 data. *Microb Genom.* Mar 2022;8(3)doi:10.1099/mgen.0.000794
- 1035 124. Garcia-Bermudez J, Baudrier L, La K, et al. Aspartate is a limiting metabolite for
1036 cancer cell proliferation under hypoxia and in tumours. *Nat Cell Biol.* Jul 2018;20(7):775-
1037 781. doi:10.1038/s41556-018-0118-z
- 1038 125. Krall AS, Xu S, Graeber TG, Braas D, Christofk HR. Asparagine promotes cancer
1039 cell proliferation through use as an amino acid exchange factor. *Nat Commun.* Apr 29
1040 2016;7:11457. doi:10.1038/ncomms11457
- 1041 126. Halbrook CJ, Thurston G, Boyer S, et al. Differential integrated stress response and
1042 asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma
1043 cells. *Nat Cancer.* Nov 2022;3(11):1386-1403. doi:10.1038/s43018-022-00463-1
- 1044 127. Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy
1045 metabolism and autophagy in the mammalian colon. *Cell Metab.* May 4 2011;13(5):517-26.
1046 doi:10.1016/j.cmet.2011.02.018
- 1047 128. Mashimo T, Pichumani K, Vemireddy V, et al. Acetate is a bioenergetic substrate for
1048 human glioblastoma and brain metastases. *Cell.* Dec 18 2014;159(7):1603-14.
1049 doi:10.1016/j.cell.2014.11.025

- 1050 129. Lyssiotis CA, Cantley LC. Acetate fuels the cancer engine. *Cell*. Dec 18
1051 2014;159(7):1492-4. doi:10.1016/j.cell.2014.12.009
- 1052 130. Comerford SA, Huang Z, Du X, et al. Acetate dependence of tumors. *Cell*. Dec 18
1053 2014;159(7):1591-602. doi:10.1016/j.cell.2014.11.020
- 1054 131. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect
1055 dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. *Mol*
1056 *Cell*. Nov 30 2012;48(4):612-26. doi:10.1016/j.molcel.2012.08.033
- 1057 132. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to
1058 Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. *Cell*. Jun 2
1059 2016;165(6):1332-1345. doi:10.1016/j.cell.2016.05.041
- 1060 133. van der Hee B, Wells JM. Microbial Regulation of Host Physiology by Short-chain
1061 Fatty Acids. *Trends Microbiol*. Aug 2021;29(8):700-712. doi:10.1016/j.tim.2021.02.001
- 1062 134. Li Z, Wang Q, Huang X, et al. Lactate in the tumor microenvironment: A rising star
1063 for targeted tumor therapy. *Front Nutr*. 2023;10:1113739. doi:10.3389/fnut.2023.1113739
- 1064 135. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T Cells in
1065 Colorectal Carcinoma. *JAMA Oncol*. Aug 2015;1(5):653-61.
1066 doi:10.1001/jamaoncol.2015.1377
- 1067 136. Kim HS, Kim CG, Kim WK, et al. Fusobacterium nucleatum induces a tumor
1068 microenvironment with diminished adaptive immunity against colorectal cancers. *Front Cell*
1069 *Infect Microbiol*. 2023;13:1101291. doi:10.3389/fcimb.2023.1101291
- 1070 137. Kosumi K, Baba Y, Yamamura K, et al. Intratumour Fusobacterium nucleatum and
1071 immune response to oesophageal cancer. *Br J Cancer*. Apr 2023;128(6):1155-1165.
1072 doi:10.1038/s41416-022-02112-x
- 1073 138. Dahlstrand Rudin A, Khamzeh A, Venkatakrishnan V, Basic A, Christenson K,
1074 Bylund J. Short chain fatty acids released by Fusobacterium nucleatum are neutrophil
1075 chemoattractants acting via free fatty acid receptor 2 (FFAR2). *Cell Microbiol*. Aug
1076 2021;23(8):e13348. doi:10.1111/cmi.13348
- 1077 139. Mendes RT, Nguyen D, Stephens D, et al. Endothelial Cell Response to
1078 Fusobacterium nucleatum. *Infect Immun*. Jul 2016;84(7):2141-2148. doi:10.1128/iai.01305-
1079 15
- 1080 140. Wang Q, Zhao L, Xu C, Zhou J, Wu Y. Fusobacterium nucleatum stimulates
1081 monocyte adhesion to and transmigration through endothelial cells. *Arch Oral Biol*. Apr
1082 2019;100:86-92. doi:10.1016/j.archoralbio.2019.02.013
- 1083 141. Wright HJ, Chapple IL, Matthews JB, Cooper PR. Fusobacterium nucleatum
1084 regulation of neutrophil transcription. *J Periodontal Res*. Feb 2011;46(1):1-12.
1085 doi:10.1111/j.1600-0765.2010.01299.x
- 1086 142. Zhou T, Meng X, Wang D, Fu W, Li X. Neutrophil Transcriptional Deregulation by
1087 the Periodontal Pathogen Fusobacterium nucleatum in Gastric Cancer: A Bioinformatic
1088 Study. *Dis Markers*. 2022;2022:9584507. doi:10.1155/2022/9584507
- 1089 143. Neuzillet C, Marchais M, Vacher S, et al. Prognostic value of intratumoral
1090 Fusobacterium nucleatum and association with immune-related gene expression in oral
1091 squamous cell carcinoma patients. *Sci Rep*. Apr 12 2021;11(1):7870. doi:10.1038/s41598-
1092 021-86816-9
- 1093 144. Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal
1094 carcinoma tissue and patient prognosis. *Gut*. Dec 2016;65(12):1973-1980.
1095 doi:10.1136/gutjnl-2015-310101
- 1096 145. Lehr K, Nikitina D, Vilchez-Vargas R, et al. Microbial composition of tumorous and
1097 adjacent gastric tissue is associated with prognosis of gastric cancer. *Sci Rep*. Mar 21
1098 2023;13(1):4640. doi:10.1038/s41598-023-31740-3


- 1099 146. Hsieh YY, Kuo WL, Hsu WT, Tung SY, Li C. Fusobacterium Nucleatum-Induced
1100 Tumor Mutation Burden Predicts Poor Survival of Gastric Cancer Patients. *Cancers (Basel)*.
1101 Dec 30 2022;15(1)doi:10.3390/cancers15010269
1102 147. Zhang N, Liu Y, Yang H, et al. Clinical Significance of Fusobacterium nucleatum
1103 Infection and Regulatory T Cell Enrichment in Esophageal Squamous Cell Carcinoma.
1104 *Pathol Oncol Res*. 2021;27:1609846. doi:10.3389/pore.2021.1609846
1105 148. Jo AR, Baek KJ, Shin JE, Choi Y. Mechanisms of IL-8 suppression by Treponema
1106 denticola in gingival epithelial cells. *Immunol Cell Biol*. Feb 2014;92(2):139-47.
1107 doi:10.1038/icb.2013.80
1108 149. Babolin C, Amedei A, Ozolins D, Zilevica A, D'Elis MM, de Bernard M. TpF1 from
1109 Treponema pallidum activates inflammasome and promotes the development of regulatory T
1110 cells. *J Immunol*. Aug 1 2011;187(3):1377-84. doi:10.4049/jimmunol.1100615
1111 150. Hashimoto M, Asai Y, Ogawa T. Treponemal phospholipids inhibit innate immune
1112 responses induced by pathogen-associated molecular patterns. *J Biol Chem*. Nov 7
1113 2003;278(45):44205-13. doi:10.1074/jbc.M306735200
1114 151. Kataoka H, Taniguchi M, Fukamachi H, Arimoto T, Morisaki H, Kuwata H. Rothia
1115 dentocariosa induces TNF-alpha production in a TLR2-dependent manner. *Pathog Dis*. Jun
1116 2014;71(1):65-8. doi:10.1111/2049-632x.12115
1117 152. Hawkes CG, Hinson AN, Vashishta A, et al. Selenomonas sputigena Interactions with
1118 Gingival Epithelial Cells That Promote Inflammation. *Infect Immun*. Feb 16
1119 2023;91(2):e0031922. doi:10.1128/iai.00319-22
1120 153. Xu Z, Lv Z, Chen F, et al. Dysbiosis of human tumor microbiome and aberrant
1121 residence of Actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer.
1122 *Front Immunol*. 2022;13:1008975. doi:10.3389/fimmu.2022.1008975
1123

1124 **Supplementary Figures**

1125

1126

1127



1128


1129 Figure S1: CLR-normalized abundances for remaining 13 bacteria between sample groups using unpaired

1130 Kruskal-Wallis test with Bonferroni's multiple comparison. Post-hoc Wilcoxon test with Bonferroni-Dunn's

1131 multiple comparison was performed to identify group-wise differences between Cancer – Non-cancer (#),

1132 Cancer – Cancer-adjacent (*), Non-cancer – Cancer-adjacent (^).

1133



1134

1135 Figure S2: Beta-diversity between paired cancer and cancer-adjacent tissue samples. Paired Wilcoxon test was
1136 performed on Euclidean distance between each samples. No significant differences between cancer and cancer-
1137 adjacent tissue samples.

1138